瘤微环境中的葡萄糖溶解驱动的免疫亚型确定了扩散大B细胞淋巴瘤的临床结果
Ying Du1,2, Zhenyu Liu1, Chuanyan Liu1
1Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210008, China.
Cancers
|January 10, 2026
概括
扩散型大B细胞淋巴瘤 (DLBCL) 的糖解模式与免疫细胞透和患者存活相关. 了解这些代谢状态可以改善DLBCL的预后,并指导新的治疗方法.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 代谢研究研究 代谢研究
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是最常见的非霍奇金淋巴瘤.
- 超过三分之一的DLBCL患者在初始治疗中无法实现持久缓解.
- 更好地了解DLBCL生物学对于更好的风险分层和治疗结果至关重要.
研究的目的:
- 综合评估DLBCL中的糖解相关修饰模式.
- 分析这些模式与瘤微环境 (TME) 内的免疫细胞透和预后的关联.
- 为了验证DLBCL小鼠模型中的发现.
主要方法:
- 在562个DLBCL样本中分析了30个与糖解相关的基因.
- 糖解模式,免疫细胞透和预后之间的相关性分析.
- 使用DLBCL小鼠模型进行体内验证,包括组织病理学,存活分析,西部斑点和免疫组织化学.
主要成果:
- 确定了四种不同的糖解修饰模式,与三个免疫亚型相关:免疫炎症,免疫排除和免疫荒漠.
- 免疫炎症亚型由于免疫透而表现出有利的生存率.
- 免疫性荒漠亚型与生存率差相关,而免疫性排除亚型显示没有生存优势.
结论:
- 糖溶解修饰模式与DLBCL TME中的免疫细胞透相关.
- 在DLBCL中,不同的甘油性状态与不同的临床结果有关.
- 这些发现为改善DLBCL的预后分层和治疗决策提供了一个框架.
更多相关视频
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K


